SCHEMBL8512404

SCHEMBL8512404

c1ccc(COc2cncc(OCc3ccccc3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.56
ALOX5 P09917 1/20 0.55
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
LMNA P02545 1/20 0.53
CYP1A2 P05177 1/20 0.53
PTGS1 P23219 1/20 0.53
SLC6A2 P23975 1/20 0.53
CYP2C19 P33261 1/20 0.53
PTGS2 P35354 1/20 0.53
SLC6A3 Q01959 1/20 0.53
HIF1A Q16665 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
MAOA P21397 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
PDGFRB P09619 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13535019 0.91 AOC3 (0.54) MAOBALOX5MEN1KMT2ALMNA
SCHEMBL4538153 0.91 MAOB (0.67) MAOBALOX5MEN1KMT2AMAPT
SCHEMBL6582384 0.89 CYP1A2 (0.56) MAOBALOX5MEN1KMT2ALMNA
SCHEMBL7237701 0.88 MAOB (0.46) MAOBALOX5MEN1KMT2ALMNA
SCHEMBL13535014 0.87 PDGFRB (0.49) MAOBALOX5MEN1KMT2ALMNA
SCHEMBL7057444 0.87 CHRNB2 (0.49) MAOBALOX5KMT2ALMNACYP1A2
SCHEMBL20832869 0.87 APP (0.53) MAOBALOX5MEN1KMT2ALMNA
SCHEMBL18479100 0.87 ALOX5 (0.47) MAOBALOX5MEN1KMT2ALMNA
SCHEMBL15049880 0.87 ALOX5 (0.47) MAOBALOX5MEN1KMT2ALMNA
SCHEMBL29764911 0.87 MAOB (0.62) MAOBALOX5LMNACYP1A2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 WO disclosed
EP-2841471-B1 ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS GRACE W R & CO (US) 2020-05-06 EP disclosed
US-20190153135-A1 Activator Compositions, Their Preparation, And Their Use In Catalysts GRACE W R & CO (US) 2019-05-23 US disclosed
US-10221264-B2 Activator compositions, their preparation, and their use in catalysts W. R. GRACE & CO.-CONN. (US) 2019-03-05 US disclosed
US-20150105238-A1 ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSTS W. R. GRACE & CO.-CONN. 2015-04-16 US disclosed
EP-2643366-B1 ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS ALBEMARLE CORP (US) 2015-03-25 EP disclosed
US-8895465-B2 Activator compositions, their preparation, and their use in catalysis ALBEMARLE CORPORATION (US) 2014-11-25 US disclosed
EP-2643366-A2 ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS Albemarle Corporation (US) 2013-10-02 EP disclosed
US-20130253155-A1 Activator Compositions, Their Preparation, and Their Use In Catalysis ALBEMARIE CORPORATION (US) 2013-09-26 US disclosed
WO-2012071205-A2 ACTIVATOR COMPOSITIONS, THEIR PREPARATION, AND THEIR USE IN CATALYSIS ALBEMARLE CORPORATION (US) 2012-05-31 WO disclosed